<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03165877</url>
  </required_header>
  <id_info>
    <org_study_id>035-2013</org_study_id>
    <nct_id>NCT03165877</nct_id>
  </id_info>
  <brief_title>Effect of Low-glycemic Index Meals Intake on DM2 Women Under Metformin Therapy</brief_title>
  <acronym>LGIM</acronym>
  <official_title>Effect of Low-glycemic Index Lunches and Dinners Intake on Indicators of Satiety, Metabolic Parameters and Liver Steatosis Degree on Women With Type 2 Diabetes Under Metformin Therapy: Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad de Valparaiso</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad de Valparaiso</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of low-glycemic index versus control lunches and dinners intake on
      indicators of satiety, metabolic parameters and liver steatosis degree on women with type 2
      diabetes under metformin therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 31, 2016</start_date>
  <completion_date type="Actual">October 13, 2016</completion_date>
  <primary_completion_date type="Actual">October 13, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline Fasting glycemia at 12 weeks</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Fasting glycemia (mg/dL) was measured at Baseline and at 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postprandial glycemia</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Postprandial glycemia (mg/dL) was measured for lunch and dinner of one day at 4, 8 and 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Glycosylated hemoglobin at 12 weeks</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Glycosylated hemoglobin was measured at Baseline and at 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Triglycerides at 12 weeks</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Triglycerides (mg/dL) was measured at Baseline and at 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Total cholesterol/HDL ratio at 12 weeks</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Total cholesterol/HDL ratio was measured at Baseline and at 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline HDL cholesterol at 12 weeks</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>HDL cholesterol (mg/dL) was measured at Baseline and at 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Total cholesterol at 12 weeks</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Total cholesterol (mg/dL) was measured at Baseline and at 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline LDL cholesterol at 12 weeks</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>LDL cholesterol (mg/dL) was measured at Baseline and at 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline High-sensitivity C-reactive protein (hs-CRP) at 12 weeks</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>High-sensitivity C-reactive protein (mg/L) was measured at Baseline and at 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Aspartate aminotransferase (AST) at 12 weeks</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Aspartate aminotransferase (UI/L) was measured at Baseline and at 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Alanine aminotransferase (ALT) at 12 weeks</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Alanine aminotransferase (UI/L) was measured at Baseline and at 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Liver steatosis degree at 12 weeks</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Liver steatosis degree was measured at Baseline, 4, 8 and 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective satiety</measure>
    <time_frame>7 days</time_frame>
    <description>Visual Analog Scale (VAS) was applied after lunches and dinners of 7 days to each subject</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective satiety</measure>
    <time_frame>7 days</time_frame>
    <description>24-hour recall was applied the same 7 days as the VAS to each subject</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body mass index (BMI)</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Body mass index (BMI) (kg/m2) was measured at Baseline, 4, 8 and 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Waist circumference (cm) was measured at Baseline, 4, 8 and 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alcohol intake</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Alcohol intake (g/day) was measured at Baseline, 4, 8 and 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Physical activity was measured at Baseline, 4, 8 and 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to treatment</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>The percentage of adherence to treatment was measured through a daily survey for 12 weeks. It is the calculation of compliance with planned meals intake (number of lunches and dinners eaten / total number of lunches and dinners of the study x 100).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Low-glycemic index</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-glycemic index lunches and dinners (&lt;55%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medium/high glycemic index lunches and dinners (&gt;60%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low-glycemic index</intervention_name>
    <description>Subjects ate low-glycemic index lunches and dinners (&lt;55%),consisting of salad, main course and dessert, respectively.</description>
    <arm_group_label>Low-glycemic index</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Subjects ate standard lunches and dinners (&gt;60%),consisting of salad, main course and dessert, respectively.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjets with type 2 diabetes mellitus diagnosis under metformin therapy.

          -  Female sex.

          -  Aged 30 to 65 years.

          -  Body Mass Index (BMI) 22 to 34.9 kg / m2.

        Exclusion Criteria:

          -  Women with insulin-releasing drugs or insulin treatment.

          -  Patients with diabetic nephropathy, retinopathy, chronic kidney disease, stroke.

          -  Subjects with hypothyroidism without treatment.

          -  Individuals with food allergies or intolerances.

          -  Women who present an intake of â‰¥20 g of alcohol per day quantified through a closed
             consumption frequency survey.

          -  Patients with previously diagnosed hepatitis, hepatic cirrhosis or liver cancer.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2017</study_first_submitted>
  <study_first_submitted_qc>May 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <last_update_submitted>May 22, 2017</last_update_submitted>
  <last_update_submitted_qc>May 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad de Valparaiso</investigator_affiliation>
    <investigator_full_name>Claudia Vega Soto</investigator_full_name>
    <investigator_title>Nutritionist</investigator_title>
  </responsible_party>
  <keyword>GLYCEMIC INDEX</keyword>
  <keyword>NAFLD</keyword>
  <keyword>METABOLIC PARAMETERS</keyword>
  <keyword>SATIETY</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

